🔬 Tofacitinib solo works just as well as combo therapy

A retrospective study compared treatment persistence for rheumatoid arthritis patients using tofacitinib. Researchers analyzed data from six Dutch cohorts, involving 2684 adults between 2001 and 2022. The findings showed no significant difference in drug survival between tofacitinib monotherapy and combination therapy across ACPA subgroups. However, adalimumab combination therapy showed a lower risk of discontinuation. This suggests solo tofacitinib is a viable option in real-world settings. 🧐

🎬 Hi recovers 28% of budget after slow start

The romance drama 'Hi' has started slow at the box office but is showing growth. Starring Nayanthara and Kavin, the film was released recently in India. Over its opening weekend, it earned a net total of 5.6 crore against a 30 crore budget. The film has recovered 28% of its production cost, driven by positive word-of-mouth. It is expected to slowly become profitable with continued audience support. 🎬

🏥 New guidelines boost sepsis care systems

Hospital-level sepsis interventions across diagnosis and antimicrobial stewardship can significantly improve patient outcomes. This new position paper, from IDSA, suggests focusing beyond initial care for better prevention. It advises using multiplex nucleic acid tests and keeping antibiotic administration times super quick. The recommendations aim to complement existing guidelines by focusing on broader systemic changes. Hospitals are encouraged to adopt expanded performance measures to refine and improve care.

🚀 Ravi Teja's Irumudi Smashes Tollywood's 2nd Sunday Record

The film Irumudi, starring Ravi Teja, is having a massive run at the Indian box office. It achieved Tollywood's biggest second Sunday of 2026 on the second Sunday, overtaking Ram Charan's Peddi. On day 10, the Telugu entertainer earned 15 crore, marking a 21.95% jump from day 9's 12.3 crore. With a budget of 35 crore, it has grossed 129.55 crore net, leading to a 270.14% ROI. The film is currently on track to cross the 200 crore net collections mark. 📈

🧠 ALS blood marker links to new treatment hope

Researchers identified elevated blood levels of N-acyl taurines as a marker for rapidly progressing ALS in Japan. These NATs were found to correlate with shorter survival times in patients. In experiments using patient cells and mouse models, a compound targeting NAT breakdown slowed motor decline and extended survival. This suggests a new drug discovery route starting from patient metabolic changes. Future studies are needed to confirm NATs as a practical biomarker and understand the full mechanism. 🔬

🔬 Tiny device detects cancer and HIV at home

Researchers developed the VPodDuoss, a handheld device capable of detecting pathogens and cancer biomarkers without needing a lab. Han-Keun Lee and his team at the University of Illinois Urbana-Champaign created this by miniaturizing complex fluorescence assay technology. Promising results were published in IEEE Sensors Journal in July 2026, showing comparable accuracy to lab-grade fluorimeters for HIV and lung cancer. The device, which is about the size of AirPods, aims to make point-of-care diagnostics more accessible. The team is now working on improving automation before aiming to bring the technology to the market. 🔬

🚀 Nivin Pauly's film hits super hit status

Nivin Pauly and Mamitha Baiju's 'Bethlehem Kudumba Unit' is showing massive success at the box office. The Malayalam film is performing strongly both domestically and overseas. In 10 days, it earned 82.45 crore net in India and 10 crore overseas, hitting a worldwide gross of 195.79 crore. Based on a 30 crore budget, the film has already secured a 174% return on investment. It is expected to reach the 200% return milestone by Tuesday after the Onam holidays end. 🎬

🩺 Cerebral Palsy affects preventive women's health care

Women with cerebral palsy were found to be significantly less likely to receive routine gynecologic screenings and mammograms. The study analyzed US women aged 20-69 using insurance claims data from 2010 through Q1 2022. Specifically, they had 85% lower odds for exams and 74% lower odds for Pap tests. Researchers suggest this lack of preventive care could seriously impact health quality across all age groups. Future steps require addressing this multifactorial disparity in healthcare access. 🩺

🤧 Nasal spray helps with severe allergies

Pumecitinib nasal spray reduced nasal and eye symptoms in adults with moderate-to-severe seasonal allergic rhinitis. The Phase 2 trial took place across 20 sites in China from March to June 2024, involving 168 adults. Doses of 1.2 mg and 2.0 mg showed significant symptom reduction compared to the placebo group. Overall quality of life improved across all active doses when compared against the placebo. The results suggest this spray offers a viable treatment option for allergy sufferers. 🤧

🧠 New stroke rehab guidelines push for earlier care

A new American Stroke Association guideline prioritizes early and personalized rehab for stroke recovery. This update recommends starting rehabilitation within 48 hours of stroke when medically stable across various needs. The guideline was published online on August 27, addressing nearly 800,000 annual stroke cases in the US. It significantly expands recommendations on mental health, cognition, and sleep management during recovery. Future focus includes tailoring interventions and leveraging technology like telehealth for patients. 🧠

🦠 Atypical CDI linked to worse outcomes and delays

Atypical presentations of Clostridioides difficile infection (CDI) without initial diarrhea were found to cause delayed treatment and double the 90-day mortality. This study was conducted on hospitalized adults in a tertiary health service in Australia between January 2018 and December 2021. Among 467 CDI episodes, atypical cases represented 19.5% and showed significantly delayed treatment compared to typical ones. Gastrointestinal dysmotility was noted in 32% of episodes at diagnosis and persisted for up to 6 weeks. The authors suggest expanding CDI guidelines to recognize these atypical signs to lower global mortality. 🦠